152 related articles for article (PubMed ID: 11458048)
1. Chemosensitization of bladder carcinoma cells by bcl-xL antisense oligonucleotides.
Lebedeva I; Raffo A; Rando R; Ojwang J; Cossum P; Stein CA
J Urol; 2001 Aug; 166(2):461-9. PubMed ID: 11458048
[TBL] [Abstract][Full Text] [Related]
2. Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity.
Lebedeva I; Rando R; Ojwang J; Cossum P; Stein CA
Cancer Res; 2000 Nov; 60(21):6052-60. PubMed ID: 11085527
[TBL] [Abstract][Full Text] [Related]
3. Response of bladder carcinoma cells to TRAIL and antisense oligonucleotide, Bcl-2 or clusterin treatments.
Sun B; Moibi JA; Mak A; Xiao Z; Roa W; Moore RB
J Urol; 2009 Mar; 181(3):1361-71. PubMed ID: 19157446
[TBL] [Abstract][Full Text] [Related]
4. The effect of antisense Bcl-2 oligonucleotides on Bcl-2 protein expression and apoptosis in human bladder transitional cell carcinoma.
Duggan BJ; Maxwell P; Kelly JD; Canning P; Anderson NH; Keane PF; Johnston SR; Williamson KE
J Urol; 2001 Sep; 166(3):1098-105. PubMed ID: 11490306
[TBL] [Abstract][Full Text] [Related]
5. Antisense RNA down-regulation of bcl-xL Expression in prostate cancer cells leads to diminished rates of cellular proliferation and resistance to cytotoxic chemotherapeutic agents.
Vilenchik M; Raffo AJ; Benimetskaya L; Shames D; Stein CA
Cancer Res; 2002 Apr; 62(7):2175-83. PubMed ID: 11929841
[TBL] [Abstract][Full Text] [Related]
6. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells.
Zangemeister-Wittke U; Leech SH; Olie RA; Simões-Wüst AP; Gautschi O; Luedke GH; Natt F; Häner R; Martin P; Hall J; Nalin CM; Stahel RA
Clin Cancer Res; 2000 Jun; 6(6):2547-55. PubMed ID: 10873111
[TBL] [Abstract][Full Text] [Related]
7. Bcl-XL antisense oligonucleotides coupled with antennapedia enhances radiation-induced apoptosis in pancreatic cancer.
Masui T; Hosotani R; Ito D; Kami K; Koizumi M; Mori T; Toyoda E; Nakajima S; Miyamoto Y; Fujimoto K; Doi R
Surgery; 2006 Aug; 140(2):149-60. PubMed ID: 16904964
[TBL] [Abstract][Full Text] [Related]
8. Modulation of apoptosis by endogenous Bcl-xL expression in MKN-45 human gastric cancer cells.
Kondo S; Shinomura Y; Kanayama S; Higashimoto Y; Kiyohara T; Zushi S; Kitamura S; Ueyama H; Matsuzawa Y
Oncogene; 1998 Nov; 17(20):2585-91. PubMed ID: 9840921
[TBL] [Abstract][Full Text] [Related]
9. Antisense protein kinase A RIalpha acts synergistically with hydroxycamptothecin to inhibit growth and induce apoptosis in human cancer cells: molecular basis for combinatorial therapy.
Cho YS; Cho-Chung YS
Clin Cancer Res; 2003 Mar; 9(3):1171-8. PubMed ID: 12631623
[TBL] [Abstract][Full Text] [Related]
10. Expression and role of Bcl-xL in human hepatocellular carcinomas.
Takehara T; Liu X; Fujimoto J; Friedman SL; Takahashi H
Hepatology; 2001 Jul; 34(1):55-61. PubMed ID: 11431734
[TBL] [Abstract][Full Text] [Related]
11. Apoptotic responsiveness of PC-3 prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand: evidence for differential effects of Bcl-xL and Bcl-2 down-regulation.
Sonnemann J; Gekeler V; Sagrauske A; Müller C; Hofmann HP; Beck JF
Int J Oncol; 2004 Oct; 25(4):1171-81. PubMed ID: 15375570
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.
Jazirehi AR; Vega MI; Chatterjee D; Goodglick L; Bonavida B
Cancer Res; 2004 Oct; 64(19):7117-26. PubMed ID: 15466208
[TBL] [Abstract][Full Text] [Related]
13. Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL.
Amarante-Mendes GP; McGahon AJ; Nishioka WK; Afar DE; Witte ON; Green DR
Oncogene; 1998 Mar; 16(11):1383-90. PubMed ID: 9525737
[TBL] [Abstract][Full Text] [Related]
14. [Effect of phosphorothioate antisense Bcl-xL oligodeoxynucleotides on apoptosis and thermosensitivity of BcaCD885 cells].
He YW; Bian L; Liang XH
Hua Xi Kou Qiang Yi Xue Za Zhi; 2004 Apr; 22(2):112-4. PubMed ID: 15190790
[TBL] [Abstract][Full Text] [Related]
15. Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.
Villedieu M; Louis MH; Dutoit S; Brotin E; Lincet H; Duigou F; Staedel C; Gauduchon P; Poulain L
Gynecol Oncol; 2007 Apr; 105(1):31-44. PubMed ID: 17275076
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Bcl-xL expression sensitizes normal human keratinocytes and epithelial cells to apoptotic stimuli.
Taylor JK; Zhang QQ; Monia BP; Marcusson EG; Dean NM
Oncogene; 1999 Aug; 18(31):4495-504. PubMed ID: 10442640
[TBL] [Abstract][Full Text] [Related]
17. Human colon cancer cells lacking Bax resist curcumin-induced apoptosis and Bax requirement is dispensable with ectopic expression of Smac or downregulation of Bcl-XL.
Rashmi R; Kumar S; Karunagaran D
Carcinogenesis; 2005 Apr; 26(4):713-23. PubMed ID: 15661804
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of protein kinase Ceta by antisense oligonucleotides sensitises A549 lung cancer cells to vincristine and paclitaxel.
Sonnemann J; Gekeler V; Ahlbrecht K; Brischwein K; Liu C; Bader P; Müller C; Niethammer D; Beck JF
Cancer Lett; 2004 Jun; 209(2):177-85. PubMed ID: 15159020
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-6 is responsible for drug resistance and anti-apoptotic effects in prostatic cancer cells.
Pu YS; Hour TC; Chuang SE; Cheng AL; Lai MK; Kuo ML
Prostate; 2004 Jul; 60(2):120-9. PubMed ID: 15162378
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of cytotoxic effects induced by bcl-2 and bcl-xL antisense-oligodeoxynucleotides in normal urothelium and transitional cell carcinoma.
Gabriel U; Bolenz C; Becker A; Schaaf A; Steidler A; Trojan L; Weiss C; Michel MS
Oncol Rep; 2008 Dec; 20(6):1419-23. PubMed ID: 19020723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
